Proteomics

Dataset Information

0

The HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues


ABSTRACT: The human leukocyte antigen (HLA) complex regulates the adaptive immune response by showcasing the intracellular and extracellular protein content to the immune system. T cells recognize these HLA-presented peptides as self or foreign and can elicit an immune response. In this work, we describe the HLA-Ligand-Atlas, a comprehensive map of HLA-I and HLA-II-presented peptides from 30 benign tissues, 51 HLA-I alleles, and 86 HLA-II alleles. Nearly 50% of HLA ligands have not been previously described. Due to the scarcity of benign human samples, the tissue was extracted from different organs at autopsy from human subjects without any diagnosed malignancy. Furthermore, we were able to identify non-canonical HLA-I peptides on benign tissues, showing that their processing is not unique to cancer. This dataset holds great promise in answering both basic and translational questions in fields such as autoimmunity, organ/tissue transplantation, and cancer immunotherapy.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Heart, Testis, Cerebellum, Brain, Tongue, Prostate Gland, Lung, Liver, Bladder, Lymph Node, Kidney, Thymus, Nerve, Ovary, Uterus, Aorta, Muscle, Colon, Pancreas, Bone Marrow, Trachea, Spleen, Stomach, Gall Bladder, Thyroid Gland, Esophagus, Breast, Skin, Adrenal Gland, Small Intestine

SUBMITTER: Ana Marcu  

LAB HEAD: Hans-Georg Rammensee

PROVIDER: PXD019643 | Pride | 2021-04-16

REPOSITORIES: Pride

altmetric image

Publications


<h4>Background</h4>The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite to define safe T-cell-based immunotherapies against cancer. Due to the poor availability of benign tissues, if available, normal tissue adjacent to the tumor has been used as a benign surrogate when defining tumor-associated antigens. However,  ...[more]

Similar Datasets

2021-04-16 | PXD020186 | Pride
2019-03-12 | PXD009602 | Pride
2022-05-31 | PXD033935 | Pride
2017-11-02 | PXD007635 | Pride
2020-04-03 | PXD017149 | Pride
2019-12-11 | PXD015947 | Pride
2018-12-11 | PXD010450 | Pride
2021-09-10 | PXD024871 | Pride
2022-09-22 | PXD024417 | Pride
2021-09-10 | PXD023614 | Pride